Correlations of Hemoglobin Level and Perioperative Blood Transfusion with the Prognosis of Gastric Cancer: A Retrospective Study

ABE 1 Gang Wu
BCE 2 Dai-Yang Zhang
CF 3 Yu-Han Duan
EF 4 Ying-Qiong Zhang
CD 5 Xian-Nian Cui
ABCE 2 Zheng Luo

Background: This study was designed to explore the correlations of hemoglobin level (Hb) and perioperative blood transfusion with the prognosis of gastric cancer (GC).

Material/Methods: Our study consisted of 210 patients with GC who all received a D2 radical operation. These patients were assigned into three groups: 68 cases in group A (blood transfusion >5 U); 59 cases in group B (blood transfusion ≤5 U); 83 cases in group C (without blood transfusion). A 5-year follow-up was conducted to evaluate the disease-free survival of the patients. Univariate analysis was performed to reveal the relationship between the indicators and the patients with GC. Kaplan-Meier method was employed to analyze the survival rate of patients, and Cox regression analysis was applied to determine the independent prognostic factors of GC.

Results: The univariate analysis indicated that age, perioperative blood transfusion amount, TNM staging, maximal tumor diameter, differentiation degree and invasion degree were associated with the prognosis of GC. The Kaplan-Meier curve showed that the disease-free survival rate was declined in the patients who were older, those received more amount of blood transfusion, those in advanced TNM staging, those had larger tumor diameter, and those with decreased degree of differentiation and invasion. Cox regression analysis indicated that perioperative blood transfusion, maximal tumor diameter and invasion degree were the independent factors affecting disease-free survival of the GC.

Conclusions: Our study revealed that large amount of perioperative blood transfusion leads to poor prognosis of GC.

MeSH Keywords: Blood Transfusion • Disease-Free Survival • Hemoglobin A • Perioperative Period • Prognosis

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900907
Background

Gastric cancer (GC), developing from the lining of the stomach, is the fifth major cause of cancer incidence and also the third major cause of cancer-associated death worldwide [1]. It is recorded there are 989,600 newly diagnosed GC cases and 738,000 deaths from this disease worldwide in 2008 and approaching 70% of these cases occurred in the developing countries [2]. The 5-year survival rate of patients diagnosed with operable disease who receive perioperative chemotherapy is 36%, unfortunately, the 5-year survival of patients with advanced or metastatic GC is only 5–20% with mean overall survival no longer than one year [3,4]. Currently, surgical treatment is the most important approach for GC, and radical resection is the only means for GC patients being cured [5].

To our knowledge, the radical treatment for GC is shown to combine the radical gastrectomy together with dissection of regional lymph node, and D2 gastrectomy is now strongly recommended in the treatment for patients diagnosed with advanced GC around the world [5,6]. Unfortunately, gastrectomy with lymphadenectomy often results in long operation time, overwhelming bleeding and significant increases of minor complications [7]. During the surgery, especially perioperative period, such as gastrectomy and lymphadenectomy, blood transfusion is often required due to the complexity of GC and excessive blood loss [8,9]. Interestingly, recent evidence demonstrated that anemia was implicated in the long-term survival and prognosis of GC patients [10]. Additionally, the Hb levels could affect quality of life improvements in anemic cancer patients [11]. In this respect, understanding the potential relationship between Hb levels and perioperative blood transfusion, and prognosis of GC would help to provide the theoretic basis for the prognostic improvement of GC. However, the relationship between perioperative allogeneic blood transfusions and poor prognosis in patients with GC still remains controversial [12]. Recently, prognostic effects of perioperative blood transfusions on GC patients has been analyzed through retrospective study, while in our prospective research, we investigated the prognostic significance of Hb level and perioperative blood transfusion and how these two factors influenced the survival rate of GC patients.

Material and Methods

Patients

A total of 210 GC patients (128 males and 82 females, age between 36 and 79 years, with median age of 60 years) with complete follow-up data, diagnosed and treated in Spinal Surgical Diagnosis and Treatment Center, The Central Hospital of Hubei Enshi Tujia and Miao Autonomous Prefecture between October 2008 and December 2010, were enrolled into our study. The degree of differentiation was: 49 well differentiated cases, 62 moderately differentiated cases, and 99 poorly differentiated cases. Tumor location was: 65 cases located in gastric antrum area, 79 cases located in gastric antrum junction, and 66 cases located in fundus ventriculi or gastric body region. TNM staging [13] was: 47 cases in Stage I, 49 cases in Stage II, and 144 cases in Stage III. Tumor diameter was: 121 cases at ≤5 cm and 89 cases at ≥5 cm. The degree of invasion was: 34 cases at T1 level, 28 cases at T2 level, 78 cases at T3 level, and 70 cases at T4 level. According to the amount of blood transfused during the perioperative period, the patients were divided into three groups with 68 cases in group A (blood transfusion >5 U), 59 cases in group B (blood transfusion <5 U), and 83 cases in group C (without blood transfusion). Diagnostic criteria [14] was hard mass with nodules in the upper abdomen accompanied by tenderness and lymph node enlargement at the left clavicle; reduction of gastric juices and decreased gastric acidity; 60–80% showing persistent positive fecal occult blood tests. Inclusion criteria was: patients confirmed as GC by preoperative gastroscopy and tissue biopsy; patients receiving no anti-tumor therapy before the operation; and patients undergoing laparoscopic operation or open D2 radical gastrectomy. Exclusion criteria: was patients receiving preoperative anti-tumor therapies including neoadjuvant chemotherapy and radiation therapy; advanced patients undergoing palliative operation; and patients with other metabolic diseases like diabetes mellitus, hyperthyroidism, and hypothyroidism. This study was approved by the Ethics Committee of Spinal Surgical Diagnosis and Treatment Center, The Central Hospital of Hubei Enshi Tujia and Miao Autonomous Prefecture, and informed consent was obtained from each participant.

Operation method

After endotracheal intubation with general anesthesia, the patient was placed in the supine position with legs set apart. The incision was about 15–20 cm in the middle of the abdomen, then, the abdomen was cut step by step, such that the abdominal cavity was comprehensively explored. The D2 radical gastrectomy for GC was performed in accordance with Japanese classification of gastric carcinoma: 3rd English edition [15], and the lymph nodes in 11p, 7, 9, 8a, 12a and 12p group were cleared from left to right and from down to up. Catheters and peritoneal drainage tubes were indwelled after the operation. Adjuvant chemotherapy of capecitabine combined with oxaliplatin was performed postoperatively for patients, except for patients who could not take combined chemotherapy. The concentration of capecitabine was 1,000 mg/m². Patients were expected to take capecitabine two times per day, after a meal, once in the morning and once in the evening for 14 consecutive days. An intravenous infusion of 130 mg/m² oxaliplat- in was given on the first day of capecitabine therapy, and 21 expected to take capecitabine two times per day, after a meal, once in the morning and once in the evening for 14 consecutive days. An intravenous infusion of 130 mg/m² oxaliplat- in was given on the first day of capecitabine therapy, and 21 days was considered one cycle; there were a total of six cycles.
Peripheral venous blood was collected in the hospital for routine blood examination from each patient within 24 hours prior to their radical resection. Preoperative Hb was detected by blood cell detection classification technique [16], and the patients with less than 6 g/dL Hb were assigned to the severe anemia group, while the patients with more than 6 g/dL Hb were classified into the non-severe anemia group. In addition, patients with 

Comparisons of Hb levels of GC patients in the three groups

There was no significant difference in age, gender, TNM staging, maximal tumor diameter, differentiation degree, tumor location, and invasion degree between the severe anemia group and non-severe anemia group (all \( p > 0.05 \)) (Table 2).

Univariate analysis of the 5-year disease-free survival of GC patients

As shown in the single-factor analysis, gender, preoperative ALB, TP and Hb, and tumor location failed to have an effect on the prognosis of GC (all \( p > 0.05 \)) while age, perioperative blood transfusion amount, TNM staging, maximal tumor diameter, differentiation degree and invasion degree were associated with the prognosis of GC (all \( p < 0.05 \)) (Table 3). Kaplan-Meier analysis of enrolled age, perioperative blood transfusion amount, TNM staging, maximal tumor diameter, differentiation degree and invasion degree found that the disease-free survival rate was significantly lower in the patients who were older, those who received larger volume of blood transfusion, those in advanced TNM stage, those who had larger tumor diameter, and those with higher degree of differentiation and invasion (all \( p < 0.05 \)) (Figure 1).

Cox regression analysis of the independent prognostic factors for GC patients

All variables in the univariate analysis were added into Cox risk ratio function. It was suggested that the independent factors affecting disease-free survival of the GC patients were as follows: perioperative blood transfusion amount (\( p < 0.05 \), the median disease-free survival was 28 months for the patients with more than 5 U perioperative blood transfusion, 41 months for the patients with less than 5 U perioperative blood transfusion, and 48 months for the patients with no blood transfusion), maximal tumor diameter (\( p < 0.05 \), the median disease-free survival was 32 months for the patients with maximal tumor diameter more than 5 cm and 52 months for the patients with maximal tumor diameter less than 5 cm) and invasion degree (\( p < 0.05 \), the median disease-free survival was 27 months for the patients at T4 levels, 42 months for the patients at T3 levels, 48 months for the patients at T2 levels, and 53 months for patients at T1 level). However, age, gender, preoperative ALB, TP and Hb, differentiation degree, TNM staging, and tumor location were non-major prognostic factors (Table 4).

Discussion

In this study, we recruited 210 GC patients as our study population to investigate the prognostic impacts of Hb level and
perioperative blood transfusion on gastric cancer (GC) patients. On the basis of the preoperative Hb level, intraoperative blood transfusion, and follow-up, we concluded that perioperative blood transfusion was a risk factor for the prognosis of GC patients, indicating that a larger volume of perioperative blood transfusion may shorten the disease-free survival of patients. However, we did not find a relationship between Hb level and prognosis of GC. Previous studies have shown that the amount of blood transfusion of patients receiving curative surgery for GC was related to the long-term prognosis based on the predicted outcomes of all-cause mortality, cancer-related death and recurrence [9,17].

In our study, the amount of perioperative blood transfusion was significantly elevated with increased age, declined Hb, enhanced TNM stage, enlarged tumor diameter, and strengthened invasion degree. According to Yamashita et al., patients diagnosed with advanced GC commonly present with both hematogenous

| Table 1. Comparisons of clinicopathological characteristics of patients with gastric cancer among the group A (blood transfusion >5 µ), group B (blood transfusion ≤5 µ) and group C (without blood transfusion). |
|-----------------------------------------------|
| Characteristic                          | Group A (n=68) | Group B (n=59) | Group C (n=83) | P value |
|-----------------------------------------------|
| Age (years)                                 |               |               |               | <0.001 |
| <60                                          | 16            | 23            | 59            |        |
| ≥60                                          | 52            | 36            | 24            |        |
| Gender                                       |               |               |               | 0.915  |
| Male                                         | 41            | 35            | 52            |        |
| Female                                       | 27            | 24            | 31            |        |
| Preoperative ALB (g/dl)                      | 36.05±3.21    | 35.21±3.24    | 34.92±4.01    | 0.142  |
| Preoperative TP (g/dl)                       | 66.17±4.15    | 65.39±4.27    | 65.62±5.01    | 0.602  |
| Preoperative Hb (g/dl)                       | 6.97±2.18     | 9.15±2.72     | 10.52±2.14    | <0.001 |
| TNM staging                                  |               |               |               | 0.003  |
| I                                            | 6             | 15            | 26            |        |
| II                                           | 13            | 14            | 22            |        |
| III                                          | 49            | 30            | 35            |        |
| Tumor diameter                               |               |               |               | 0.004  |
| <5 cm                                        | 28            | 38            | 55            |        |
| ≥5 cm                                        | 40            | 21            | 28            |        |
| Differentiation degree                       |               |               |               | <0.001 |
| Well-differentiated                          | 12            | 9             | 28            |        |
| Moderately differentiated                    | 13            | 16            | 33            |        |
| Poorly differentiated                        | 43            | 34            | 22            |        |
| Tumor location                               |               |               |               | 0.973  |
| Gastric antrum                               | 22            | 19            | 24            |        |
| Gastric antrum junction                      | 25            | 23            | 31            |        |
| Other                                        | 21            | 17            | 28            |        |
| Invasion degree                              |               |               |               | <0.001 |
| T1                                           | 11            | 11            | 12            |        |
| T2                                           | 1             | 1             | 26            | <0.001 |
| T3                                           | 9             | 26            | 43            |        |
| T4                                           | 47            | 21            | 2             |        |

ALB – albumin; TP – total protein; Hb – hemoglobin; TNM – tumor node metastasis
and lymphatic metastatic progression [18], possibly leading to difficulties in surgery such as excessive blood loss and greater incidence of postoperative complications compared with the patients with early stage of GC. Previous research reported by Kanda et al. indicated that GC patients with older age, lower preoperative Hb levels, larger tumor size, more deep invasion, and higher pathological UICC stage were more likely to receive blood transfusions, which is indirectly consistent with our results [19]. Importantly, by Cox regression analysis, we also find that the perioperative blood transfusion amount was the independent factor affecting disease-free survival of GC patients. It has been suggested that perioperative blood transfusion is connected with inflammatory response as well as immunosuppression, and developing postoperative morbidity may occur in patients who received blood transfusion [20].

| Characteristic                  | Preoperative Hb level | P value |
|--------------------------------|-----------------------|---------|
|                                | Severe anemia group (n=53) | Non-severe anemia group (n=157) |
| Age (years)                    |                       |         |
| <60                            | 23                    | 75      |
| ≥60                            | 30                    | 82      |
| Gender                         |                       |         |
| Male                           | 36                    | 92      |
| Female                         | 17                    | 65      |
| TNM staging                    |                       |         |
| I                              | 9                     | 39      |
| II                             | 16                    | 33      |
| III                            | 29                    | 85      |
| Tumor diameter                 |                       |         |
| <5 cm                          | 33                    | 88      |
| ≥5 cm                          | 20                    | 69      |
| Differentiation degree         |                       |         |
| Well-differentiated            | 16                    | 33      |
| Moderately differentiated      | 18                    | 44      |
| Poorly differentiated          | 19                    | 80      |
| Tumor location                 |                       |         |
| Gastric antrum                 | 14                    | 51      |
| Gastric antrum junction        | 16                    | 63      |
| Other                          | 23                    | 43      |
| Invasion degree                |                       |         |
| T1                             | 13                    | 21      |
| T2                             | 11                    | 21      |
| T3                             | 4                     | 24      |
| T4                             | 20                    | 58      |
| T5                             | 16                    | 54      |

Hb – hemoglobin; TNM – tumor node metastasis.

Table 2. The relationship between hemoglobin levels and clinicopathological characteristics of patients with gastric cancer.
Table 3. Univariate analysis of the 5-year disease-free survival rate.

| Characteristic                          | 5-year PFS rate | P value |
|----------------------------------------|-----------------|---------|
| Age (years)                            |                 |         |
| <60                                    | 53.06% (52/98)  | 0.033   |
| ≥60                                    | 38.39% (43/112) |         |
| Gender                                 |                 |         |
| Male                                   | 43.75% (56/128) | 0.588   |
| Female                                 | 47.56% (39/82)  |         |
| Preoperative ALB (g/dL)                |                 | 0.995   |
| <35                                    | 45.26% (43/95)  |         |
| ≥35                                    | 45.22% (52/115) |         |
| Preoperative TP (g/dL)                 |                 | 0.132   |
| <65                                    | 46.74% (43/92)  |         |
| ≥65                                    | 36.44% (43/118) |         |
| Perioperative blood transfusion        |                 | <0.001  |
| Blood transfusion >5 µ                 | 22.06% (15/68)  |         |
| Blood transfusion ≤5 µ                 | 37.29% (22/59)  |         |
| Without blood transfusion              | 69.88% (58/83)  |         |
| Preoperative Hb                        |                 | 0.755   |
| Severe anemia group                    | 43.40% (23/53)  |         |
| Non-severe anemia group                | 45.86% (72/157) |         |
| TNM staging                            |                 | 0.007   |
| I                                      | 63.83% (30/47)  |         |
| II                                     | 46.94% (23/49)  |         |
| III                                    | 36.84% (42/114) |         |
| Maximal tumor diameter                 |                 | 0.004   |
| <5 cm                                  | 53.72% (65/121) |         |
| ≥5 cm                                  | 33.71% (30/89)  |         |
| Differentiation degree                 |                 | 0.006   |
| Well-differentiated                    | 61.22% (30/49)  |         |
| Moderately differentiated              | 50.00% (31/62)  |         |
| Poorly differentiated                  | 34.34% (34/99)  |         |
| Tumor location                         |                 | 0.644   |
| Gastric antrum                         | 43.08% (28/65)  |         |
| Gastric antrum junction                | 43.04% (34/79)  |         |
| Other                                  | 50.00% (33/66)  |         |
| Invasion degree                        |                 |         |
| T1                                     | 58.80%          | <0.001  |
| T2                                     | 71.40%          |         |
| T3                                     | 55.10%          |         |
| T4                                     | 17.10%          |         |

PFS – disease-free survival; ALB – albumin; TP total protein; Hb – hemoglobin; TNM – tumor node metastasis.
Figure 1. The relationship between clinicopathological characteristics and disease-free survival. (A) relationship between age and disease-free survival; (B) relationship between amount of perioperative blood transfusion and disease-free survival; (C) relationship between TNM staging and disease-free survival; (D) relationship between tumor diameter and disease-free survival; (E) relationship between differentiation degree and disease-free survival; (F) relationship between invasion degree and disease-free survival.
Table 4. Cox regression analysis of the independent prognostic factors for gastric cancer.

| Variable                        | B    | SE   | P value | OR    | 95%CI    |
|---------------------------------|------|------|---------|-------|---------|
| Age                             | 0.009| 0.206| 0.963   | 1.010 | 0.674–1.512 |
| Gender                          | 0.075| 0.204| 0.713   | 1.078 | 0.722–1.609 |
| Preoperative ALB                | −0.015| 0.029| 0.596   | 0.985 | 0.931–1.042 |
| Preoperative TP                 | 0.003| 0.022| 0.896   | 1.003 | 0.996–1.007 |
| Perioperative blood transfusion | 1.049| 0.319| 0.001   | 2.855 | 1.529–5.333 |
| Preoperative Hb                 | 0.025| 0.045| 0.579   | 1.025 | 0.938–1.120 |
| TNM stage                       | 0.055| 0.125| 0.658   | 1.057 | 0.827–1.351 |
| Tumor diameter                  | 0.463| 0.199| 0.020   | 1.589 | 1.077–2.347 |
| Differentiation degree          | 0.008| 0.113| 0.941   | 1.008 | 0.808–1.259 |
| Tumor location                  | −0.055| 0.127| 0.668   | 0.947 | 0.738–1.215 |
| Invasion degree                 | 0.247| 0.107| 0.022   | 1.280 | 1.037–1.579 |

B = regression coefficient; SE = standard error; ALB = albumin; TP = total protein; Hb = hemoglobin; TNM = tumor node metastasis; OR = odds ratio; CI = confidence interval.

hypotheses, reduction of T-cell proliferation, and inactivation of natural killer cell function, as well as driving the immune system toward a T-helper 2 response from a T-helper 1 response [21]. In addition, it has been found that after blood transfusion, non-specific immune responses, including natural killer cells, inhibition of T lymphocyte activity, and stimuli for antibody production, may suppress the differentiation of lymphocyte and production of lymphokines which restrict the mixed lymphocyte reaction and phagocyte function, resulting in poor prognosis, tumor reoccurrence, and decreased survival rates of GC patients [19,22]. Moreover, blood transfusion could promote the proliferation of tumors through inducing angiogenesis [8]. For example, Patel et al. indicated that blood transfusion stimulated endothelial cell proliferation and angiogenesis [23]. Park et al. reported that patients receiving perioperative blood transfusion were significantly older, had more comorbidity, and were more likely to have advanced disease [24]. Interestingly, the findings obtained from Cox regression analysis implied that maximal tumor diameter and invasion degree were independent factors affecting disease-free survival of GC patients. A former study also considered that the tumor size was an importantly independent prognostic factor for GC patients and pointed out that more concern should be paid to its role in the treatment of GC [25]. At the same time, another research study demonstrated that density of tumor-infiltrating lymphocytes could serve as an independent predictor of regional lymph node metastasis as well as survival in GC patients [26]. Additionally, there was no significant association found between Hb levels and clinicopathological characteristics. Cancer-related anemia is now thought to be caused by a complex interaction between the tumor cell population and the immune system, which ultimately disrupts normal erythropoiesis [27]. Different from our results, Tchekmedyian et al. found that anemia, common in cancer care, was usually related to worsened quality of life and declined physical function, indicating potentially important implications of anemia as a variable which affects the efficacy of cancer therapies [28]. Thus, with regard to the role of Hb level in the prognosis of GC, further investigations, including larger sample sizes, are needed.

Conclusions

We demonstrated that perioperative blood transfusion was negatively related to prognosis of GC patients, indicating that a larger amount of perioperative blood transfusion leads to poorer prognosis of GC. Unfortunately, an association between the Hb level and the prognosis of GC was not found, thus further studies should pay more attention to this subject. Besides, in the clinical setting, proper operative blood transfusion ought to be performed based on the specific condition of patients to achieve better postoperative quality of life. There were some limitations to our study. First, five years of follow-up was a relatively short period, longer periods of follow-up are needed to reveal the long-term influences of perioperative blood transfusion. In addition, the difference in the effect of laparoscopic radical gastrectomy and open radical gastrectomy on postoperative survival should be taken into consideration. Moreover, our finding that preoperative Hb level was not a prognostic factor for GC may have resulted from the differences in samples in severe anemia group and non-severe anemia group, and the fact that there are too many patients in advanced disease stage in our study.
CLINICAL RESEARCH

Conflicts of interests

None.

References:

1. Wang K, Liang Q, Li X et al: MDGA2 is a novel tumour suppressor co-operating with DMAP1 in gastric cancer and is associated with disease outcome. Gut, 2016; 65(10): 1619–31
2. Piazzuelo MB, Correa P: Gastric cancer: Overview. Colomb Med (Cali), 2013; 44: 192–201
3. Bang YJ, van Cutsem E, Feyereislova A et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet, 2010; 376: 687–97
4. Isik A, Peker K, Firat D et al: Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: A clinical trial. Med Sci Monit, 2014; 20: 1369–75
5. Waddell T, Verheij M, Allum W et al: Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol, 2014; 40: 584–91
6. Songun I, Putter H, Kranenburg EM et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol, 2010; 11: 439–49
7. Beavan, I: “Neatness and order”: The diaries and papers of William Knight, professor of natural philosophy, Marischal College, 1823–1844. North Scotl, 2001; 21: 129–39
8. Zhou HY, Yi W, Wang J et al: Association of perioperative allogeneic blood transfusions and prognosis of patients with gastric cancer after curative gastrectomy. Am J Surg, 2014; 208: 80–87
9. Sun C, Wang Y, Yao HS et al: Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg, 2015; 13: 102–10
10. Jun JH, Yoo JE, Lee JA et al: Anemia after gastrectomy in long-term survivors of gastric cancer: A retrospective cohort study. Int J Surg, 2016; 28: 162–68
11. Crawford J, Cella D, Cleeled CS et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 2002; 95: 888–95
12. Ojima T, van Cutsem E, Feyereislova A et al: Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg, 2009; 13: 1821–30
13. Edge SB, Compton CC: The American Joint Committee on Cancer. The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010; 17: 1471–74
14. Kato M: Diagnosis and therapies for gastric non-invasive neoplasia. World J Gastroenterol, 2015; 21: 12513–18
15. Aikou T, Hokita S, Natsugoe S: [Japanese Classification of Gastric Carcinoma (the 13th edition, June 1999): Points to be revised]. Nihon Rinsho, 2001; 59(Suppl. 4): 159–65 [in Japanese]
16. Harsha Kumar H, Gupta S, Ruhela S et al: A retrospective study on magnitude and factors associated with anemia in postnatal period from coastal South India. Ann Med Health Sci Res, 2014; 4: 775–79
17. Isik A, Okan I, Firat D et al: A new prognostic strategy for gastric carcinoma: Albumin level and metastatic lymph node ratio. Minerva Chir, 2014; 69: 147–53
18. Yamashita H, Kitayama J, Kanno N et al: Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer, 2006; 6: 147
19. Kanda M, Kobayashi D, Tanaka C et al: Adverse prognostic impact of peri-operative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016; 19: 255–63
20. Li Y, Stocchi L, Rui Y et al: Perioperative blood transfusion and postoperative outcome in patients with Crohn’s disease undergoing primary ileocolonic resection in the “Biological Era”. J Gastrointest Surg, 2015; 19: 1842–51
21. Sun CF, Hsieh YY, Ngar KW et al: Search for immunomodulatory effects of blood transfusion in gastric cancer patients: Flow cytometry of TH1/TH2 cells in peripheral blood. Ann Clin Lab Sci, 2001; 31: 171–78
22. Yamashita K, Sakuramoto S, Kikuchi S et al: Transfusion alert for patients with curable cancer. World J Surg, 2007; 31: 2315–22
23. Patel HB, Nasir FA, Nash GF et al: Enhanced angiogenesis following allogenic blood transfusion. Clin Lab Haematol, 2004; 26: 129–35
24. Park YH, Kim YJ, Kang SH et al: Association between perioperative blood transfusion and oncologic outcomes after curative surgery for renal cell carcinoma. J Cancer, 2016; 7: 965–72
25. Kunisaki C, Makino H, Takagawa K et al: Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol, 2008; 15: 1595–67
26. Lee HE, Chae SW,Lee YJ et al: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer, 2008; 99: 1704–11
27. Birgegard G, Aapro MS, Bokemeyer C et al: Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology, 2005; 68(Suppl. 1): 3–11
28. Tchekmedyan NS: Anemia in cancer patients: Significance, epidemiology, and current therapy. Oncology (Williston Park), 2002; 16: 17–24

Indexed in: [Current Contents/Clinical Medicine] [Journals Master List] [Index Medicus/EMBASE] [EMBASE/Excerpta Medica] [SCI Expanded] [ISI Alerting System] [Chemical Abstracts/CAS] [Index Copernicus]